MedTrace Logo

Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease

NCT01806896 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2017-12-14

Study results available
· View outcomes & findings →

Summary

This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.

Conditions

Interventions

DRUG

PF-02545920

* Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28. * Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals. * Treatment for 28 days.

DRUG

Placebo

\- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals. Dosing for 28 days.

DRUG

PF-02545920

* 5mg dose * Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals. * Dosing for 28 days.

DRUG

Placebo

* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals. * Dosing for 28 days.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01806896 on ClinicalTrials.gov